Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12736229 | 0.90 | TP53 (0.58) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL7901271 | 0.89 | RAB9A (0.67) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL27561722 | 0.86 | NPC1 (0.61) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL9472983 | 0.86 | RAB9A (0.61) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL1696388 | 0.86 | NPC1 (0.63) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL10223965 | 0.85 | RAB9A (0.60) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL13657383 | 0.84 | SMN1; SMN2 (0.56) | RAB9ANPC1TP53SMN1; SMN2L3MBTL1 | |
| SCHEMBL19070392 | 0.84 | ALDH1A1 (0.62) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL13657385 | 0.83 | PARP1 (0.58) | RAB9ANPC1TP53SMN1; SMN2L3MBTL1 | |
| SCHEMBL18901286 | 0.83 | ALDH1A1 (0.61) | RAB9ANPC1TP53SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | RAB9A 559/4885NPC1 1955/4885TP53 4768/4885 |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | RAB9A 1385/4885NPC1 4667/4885TP53 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.